登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06986785,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Patients with advanced HCC confirmed by histology or cytology;
入选标准第 5 条
If hepatitis B virus infection is negative or positive, the status of HBV surface antigen (HBsAg) should be confirmed by HBV serological test;
入选标准第 15 条
The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
入选标准第 9 条
Received anti-tumor therapy such as chemotherapy, radiotherapy and biological therapy within 4 weeks before the first use of study drug;
排除标准第 3 条
The cumulative dose of anthracyclines > 360 mg/m2 in previous (new) adjuvant therapy;
排除标准第 21 条
ECOG score was 0-1;
入选标准第 8 条
Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;
入选标准第 12 条
At least one measurable lesion meeting the RECIST v1.1 definition was required;
入选标准第 7 条
Other malignant tumors within 5 years before the first treatment;
排除标准第 9 条
Pregnant or lactating women;
排除标准第 22 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06986785,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Sign the informed consent form voluntarily and follow the protocol requirements; Gender is not limited; Age ≥18 years old and ≤75 years old; Expected survival time ≥3 months; Patients with advanced HCC confirmed by histology or cytology; Consent to provide archived tumor tissue samples or fresh tissue samples from the primary or metastatic lesions; At least one measurable lesion meeting the RECIST v1.1 definition was required; ECOG score was 0-1; The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0; No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; Organ function level must meet the requirements; Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN; Urinary protein ≤2+ or ≤1000mg/24h; No cirrhosis or only Child-Pugh A cirrhosis; If hepatitis B virus infection is negative or positive, the status of HBV surface antigen (HBsAg) should be confirmed by HBV serological test; For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.排除标准:Exclusion Criteria:
Patients with active central nervous system metastases; Who had participated in any other clinical trial within 4 weeks before the trial dose; Received anti-tumor therapy such as chemotherapy, radiotherapy and biological therapy within 4 weeks before the first use of study drug; Had undergone major surgery (investigator-defined) within 4 weeks before the first dose; Systemic corticosteroids or immunosuppressive therapy is required within 2 weeks before study dosing; Pulmonary disease defined as ≥ grade 3 according to NCI-CTCAE v5.0; A history of ILD/pulmonary inflammation requiring steroid treatment; Serious systemic infection within 4 weeks before screening; Patients at risk for active autoimmune disease or with a history of autoimmune disease; Other malignant tumors within 5 years before the first treatment; Human immunodeficiency virus antibody positive, active tuberculosis or hepatitis C virus infection; Poorly controlled hypertension by two antihypertensive drugs with different mechanisms; Diabetic patients with poor glycemic control; Had a history of severe cardiovascular and cerebrovascular diseases; Previous history of autologous or allogeneic stem cell, bone marrow or organ transplantation; Subjects with clinically significant bleeding or significant bleeding tendency within the previous 4 weeks were screened; Patients with massive or symptomatic effusions or poorly controlled effusions; Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large arteries or invaded the pericardium and heart; Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Prior treatment with an ADC drug with a topoisomerase I inhibitor as a toxin; Patients with a history of allergy to recombinant humanized antibodies or to any excipients of the trial drug; The cumulative dose of anthracyclines > 360 mg/m2 in previous (new) adjuvant therapy; Pregnant or lactating women; Who have a history of psychotropic drug abuse and cannot quit or have mental disorders; Other conditions for trial participation were not considered appropriate by the investigator.
引自 ClinicalTrials.gov, NCT06986785, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06986785,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。